 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...7980818283848586878889...235236» |
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
A Rare and Unique Case of Both Afferent and Efferent Loop Syndromes in a Patient With a Modified Whipple's Procedure (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_628;
She had a past medical history of stage II pancreatic adenocarcinoma for which she was treated with PPPD and chemoradiation with adjuvant FOLFIRINOX...As shown by our cause, after PPPDs either obstruction of the afferent or efferent limbs of a gastrojejunal anastomosis is a possible complication but rarely do both obstructions occur making our case a very unique presentation. Figure: Figure 1: Afferent loop obstruction relieved by insertion of a lumen-apposing metal stent (LAMS) Figure 2: Efferent loop obstruction with guidewire
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
A Case of a Pyloric Gland Adenoma Presenting as an Intramural Mass (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_501;
Although their incidence is rare, PGAs should be considered on the differential for atypical lesions visualized on endoscopy due to their malignant potential. Figure: Figure 1: Friable nodular ulceration on greater curvature of stomach (A), Intramural lesion within greater curvature at level of gastric fundus on CT scan (B)
- TRK-950 / Toray
A Ph-Ib study of TRK-950 combined with anti-cancer treatment regimens in patients with advanced solid tumors (Exhibition Hall) - Sep 3, 2022 - Abstract #AACRNCIEORTC2022AACR_NCI_EORTC_229;
P1, P1b
Preliminary clinical activity is demonstrated in pre-treated patients with encouraging response rates and high disease control rates, particularly in OC and GC. Further antitumor activity is being confirmed for cancer types for which such a notable response rate has been obtained.
- Establishment and characterization of a panel of BRAFV600E colorectal XPDX models from patients with acquired resistance to targeted therapies (Exhibition Hall) - Sep 3, 2022 - Abstract #AACRNCIEORTC2022AACR_NCI_EORTC_179;
These models are useful for evaluating next generation therapies and elucidating mechanisms of resistance to targeted therapies in V600E CRC. No
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., cisplatin / Generic mfg.
Journal: Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin. (Pubmed Central) - Sep 3, 2022
No Preoperative FOLFOX had a manageable safety profile and showed favorable short-term efficacy in patients with resectable LAESCC who were ineligible for CDDP-containing treatment.
- | Biomarker, Journal: Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer. (Pubmed Central) - Sep 3, 2022
High LMR patients have a higher risk of decreasing T stage, whereas high PLR patients have higher odds of progressing under FLOT and dying. Patients with TSR and a pathological response have better OS and lower risk of dying.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Cyramza (ramucirumab) / Eli Lilly, Opdivo (nivolumab) / Ono Pharma, BMS
Review, Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker: European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions. (Pubmed Central) - Sep 3, 2022
Beyond this, efficacy has been demonstrated with oral trifluridine/tipiracil and with single-agent nivolumab, in selected refractory patients. In this review, we highlight the positive evidence from key trials that have led to our current practice algorithm, with particular focus on the refractory advanced disease setting, discussing the areas of active research and highlighting the factors, including biomarkers and the influence of ethnicity, that contribute to therapeutic decision-making.
- | Journal, Real-world evidence: FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma - A novel validated prognostic score to facilitate treatment decision-making in real-world. (Pubmed Central) - Sep 3, 2022
After IPTW, only poor-risk patients had significantly longer median OS and TTD of overall QoL with FOLFIRINOX (OS: 6.9 months, 95%-CI 3.9-13.3; TTD: 10.6 months, 95%-CI 2.0-14.1) versus gemcitabine/nab-paclitaxel (OS: 4.0 months, 95%-CI 2.8-4.8; TTD: 4.1 months, 95%-CI 2.4-4.5). Our novel PCS may facilitate treatment decisions in clinical routine of advanced pancreatic cancer, since only poor-risk, but not favourable-risk patients, seem to benefit from intensified treatment with FOLFIRINOX.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3. (Pubmed Central) - Sep 3, 2022
P3
This could be explained by the overrepresentation of right-sided tumours and a lower secondary resection rate in older patients. The efficacy of targeted therapy was dependent on tumour sidedness in older patients with RAS WT mCRC.
- | Avastin (bevacizumab) / Roche
Journal, MSi-H Biomarker: Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? (Pubmed Central) - Sep 3, 2022
The efficacy of targeted therapy was dependent on tumour sidedness in older patients with RAS WT mCRC. Real-life data support the use of FOLFOXIRI ± bevacizumab only in BRAFV600E-mutated mCRC patients with right-sided tumours.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
No doubt about this: FOLFIRINOX is really a standard of care in this setting (Twitter) - Sep 3, 2022
- || Lumakras (sotorasib) / Amgen
Trial initiation date, Metastases: Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer (clinicaltrials.gov) - Sep 2, 2022
P1/2, N=59, Not yet recruiting, Sponsor: Devalingam Mahalingam
Real-life data support the use of FOLFOXIRI ± bevacizumab only in BRAFV600E-mutated mCRC patients with right-sided tumours. Initiation date: May 2022 --> Nov 2022
- | Imkeldi (imatinib) / Shorla Oncology
Trial completion date, Trial primary completion date, IO biomarker: AALL1631: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 2, 2022
P3, N=475, Recruiting, Sponsor: Children's Oncology Group
Initiation date: May 2022 --> Nov 2022 Trial completion date: Mar 2028 --> Mar 2027 | Trial primary completion date: Mar 2028 --> Mar 2027
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Trial primary completion date: AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 2, 2022
P2, N=87, Active, not recruiting, Sponsor: Children's Oncology Group
Trial completion date: Mar 2028 --> Mar 2027 | Trial primary completion date: Mar 2028 --> Mar 2027 Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
- | Xpovio (selinexor) / Karyopharm
Trial completion date, Trial primary completion date, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Sep 2, 2022
P1, N=390, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- | Trial completion date, Trial primary completion date: A Novel "Pediatric-Inspired" Regimen with Reduced Myelosuppressive Drugs for Adults (aged 18-60) with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 2, 2022
P2, N=39, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
New P2 trial: Watchful Waiting for Complete Responders to Therapy in Rectal Cancer (clinicaltrials.gov) - Sep 2, 2022
P2, N=30, Recruiting, Sponsor: Ascension South East Michigan
- ||| Venclexta (venetoclax) / Roche, AbbVie, navitoclax (ABT 263) / AbbVie
Enrollment open: Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax (clinicaltrials.gov) - Sep 2, 2022
P1/2, N=90, Recruiting, Sponsor: St. Jude Children's Research Hospital
Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Aug 2023 Not yet recruiting --> Recruiting
- ||| Vectibix (panitumumab) / Amgen, Takeda
P3 data, Journal: Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. (Pubmed Central) - Sep 2, 2022
P3
Not yet recruiting --> Recruiting The intensification of the upfront chemotherapy backbone in combination with panitumumab does not provide additional benefit in terms of treatment activity at the price of increased gastrointestinal toxicity in patients with RAS and BRAF wt mCRC.
- || leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
P2 data, Clinical Trial,Phase II, Journal: A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma - The Taiwan Cooperative Oncology Group T1217 study. (Pubmed Central) - Sep 2, 2022
The intensification of the upfront chemotherapy backbone in combination with panitumumab does not provide additional benefit in terms of treatment activity at the price of increased gastrointestinal toxicity in patients with RAS and BRAF wt mCRC. The study met its primary end-point, which supports further investigation on the merit of GSL in Asian elderly APC patients.
- | Vectibix (panitumumab) / Amgen, Takeda
Journal: FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314). (Pubmed Central) - Sep 2, 2022
P2
The PARLIM trial failed to demonstrate a two-year PFS rate of 65% after resection of colorectal liver metastases. The positive trends in survival endpoints may support future trials evaluating treatment with anti-EGFR agents after resection of liver metastases.
- |||| Clinical: Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer https://t.co/uNwvwTDVWT via @JAMAOnc part of @JAMANetwork (Twitter) - Sep 1, 2022
- ||||| Clinical: 🔥5-y Outcomes mFOLFIRINOX vs Gemcitabine as Adjuvant Therapy for #PancreaticCancer🔥 @JAMAOnc https://t.co/uC2wZp9Qw4 ✅PRODIGE 24 phs-III, 493 pts 👉mDFS: 21.4 vs 12.8 mo 👉5-y DFS: 26.1% vs 19.0% 👉mOS: 53.5 vs 35.5 mo 🎯FOLFIRINOX, age, grade & stage, centre 👉SOC @myESMO (Twitter) - Sep 1, 2022
- ||||| Clinical: In @JAMAOnc #OpenAccess Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for #PancreaticCancer https://t.co/NBsOj8dh7i Longer term OS data from PRODIGE 24/PA6 confirm 5y OS of 43.2% (mFOLFIRINOX) vs 31.4% (Gem), establishing this a regimen of choice when able. (Twitter) - Sep 1, 2022
- Pemazyre (pemigatinib) / Incyte, Specialised Therap
Cost-Effectiveness Analysis of a New Second-Line Treatment for Advanced Intrahepatic Cholangiocarcinoma in Taiwan: Genetic Test-Based Targeted Therapy of Pemigatinib Versus Chemotherapy of 5-FU (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2039;
The positive trends in survival endpoints may support future trials evaluating treatment with anti-EGFR agents after resection of liver metastases. The new regimen with pemigatinib is likely to be cost-effective and will plausibly gain a positive INMB when the cost of pemigatinib is reduced by more than 30%.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
WITHDRAWN: Cost-Effectiveness Analysis of Cetuximab in Treatment of Metastatic Colorectal Cancer Patients Considering RAS Gene Status (Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2000;
So, noting the willingness-to-pay threshold in the Iranian health system, 1GDP/capita ($2,422 ), Cetuximab may not be a cost-effective alternative in treating Metastatic Colorectal Cancer Patients in Iran even for RAS-WT patients. So, managed entry agreement would be the only solution for patient access to this medicine.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Real-World Data About Treatment Pattern and Outcomes of Patients With Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma in France: Results From the Fregat Database (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1965;
Among patients receiving first-line chemotherapy, 44 (25%) received second-line chemotherapy, most frequently Paclitaxel (n=10; 23%) or FOLFIRI (n=8; 18%))...A total of 120 (69%) patients met selection criteria of randomized Phase-III CheckMate 648 evaluating nivolumab + chemotherapy or nivolumab + ipilimumab in this indication and might have benefitted from these new therapeutic options. This study offers insights in current practice and outcomes in unselected French patients with URAM-ESCC before approval of ICI.
- Systematic Literature Review (SLR) and Meta-Analysis (MA) of Clinical Outcomes for Second-Line and Higher (≥2L) Targeted Therapies for Advanced Colorectal Cancer (aCRC) (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1915;
Standard treatments have demonstrated limited efficacy in previously-treated patients with biomarker-unselected aCRC, especially in later lines. Given that CRC is the 3rd most common cancer and 2nd leading cause of cancer mortality worldwide, a significant unmet medical need remains, that could be addressed by newer treatments under investigation.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
WITHDRAWN: Cost-Effectiveness Analysis of Adding Cetuximab to the Routine Regimen in Treatment of Metastatic Colorectal Cancer Patients Considering KRAS Gene Status (Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1105;
According to the willingness-to-pay threshold in the Iranian health system, which is 1GDP/capita ($2,422), Cetuximab is not a cost-effective intervention in Iran, even for KRAS-WT patients. So, Risk-sharing agreements would be the best solution for patient access to this medicine.
- 5-fluorouracil / Generic mfg.
USE OF SECOND-LINE CHEMOTHERAPY FOR ADVANCED BILIARY TRACT CANCER FOLLOWING THE ABC-06 CLINICAL TRIAL: EXPERIENCE FROM A TERTIARY CENTRE () - Aug 31, 2022 - Abstract #ILCA2022ILCA_225;
Approximately one third of patients commenced on first-line palliative chemotherapy for advanced biliary tract cancer are likely to be well enough for consideration of second-line therapy. This remains low and has not changed significantly since the ABC-06 trial results were reported; rapid deterioration and poor performance status at the time of progression following first-line treatment is the main reason.
- 5-fluorouracil / Generic mfg.
CT RADIOMIC FEATURES OF COLORECTAL CANCER LIVER METASTASIS FOR PREDICTING UPCOMING DISEASE PROGRESSION AFTER INITIAL SYSTEMIC CHEMOTHERAPY () - Aug 31, 2022 - Abstract #ILCA2022ILCA_213;
: Radiomic analysis of CT scans for CRLM is potential predictive tool for early prediction of disease progression during the course of systemic chemotherapy. Radiomic analysis of CRLM can warn early progression within two or three months and provide beneficial information to prepare alternative chemotherapeutic regimen.
- || albumin-bound paclitaxel / Generic mfg.
P2 data, Clinical Trial,Phase II, Journal: Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113). (Pubmed Central) - Aug 31, 2022
P2
Radiomic analysis of CRLM can warn early progression within two or three months and provide beneficial information to prepare alternative chemotherapeutic regimen. CA 19-9 response after multiagent ICT provides relevant prognostic and predictive information and is useful in selecting LAPC patients for explorative surgery.
- || Fruzaqla (fruquintinib) / Takeda
New P1/2 trial, Combination therapy, Metastases: Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 31, 2022
P1/2, N=46, Not yet recruiting, Sponsor: Chinese PLA General Hospital
- | uproleselan sodium (APL-106) / GlycoMimetics
Enrollment open, Enrollment change, Trial completion date, Combination therapy: NCI-2021-10020: Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane (clinicaltrials.gov) - Aug 31, 2022
P1, N=18, Recruiting, Sponsor: National Cancer Institute (NCI)
CA 19-9 response after multiagent ICT provides relevant prognostic and predictive information and is useful in selecting LAPC patients for explorative surgery. Not yet recruiting --> Recruiting | N=51 --> 18 | Trial completion date: Nov 2025 --> Nov 2024
- |||| 👉Upfront FOLFOXIRI plus Panitumumab does not improve outcome in #CRC now published in @JCO_ASCO https://t.co/Cxsjgu1rzu ✅TRIPLETE phs-III, 88% left-sided tumors 👉relative "low" ORR, and more GI toxicity ❌more is not always better... @myESMO @OncoAlert (Twitter) - Aug 30, 2022
- |||| Clinical: Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, & Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO https://t.co/aEsK3oRWiT (Twitter) - Aug 30, 2022
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Journal: Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis. (Pubmed Central) - Aug 30, 2022
A propensity score matching was performed by taking into account the following stratification factors: sex (male vs. female), age (< vs. ≥70 years old), overweight (body mass index, BMI < vs. ≥25), underweight (BMI < vs. ≥19), disease spread (early vs. advanced/metastatic), tumor type (esophagogastric cancer vs. the rest, hepatobiliary tumor vs. the rest, colorectal cancer vs. the rest), type of NK1-RA used as primary/secondary prophylaxis (netupitant-palonosetron vs. fosaprepitant/aprepitant), concomitant use of opioids (yes vs. no), concomitant use of antidepressant/antipsychotic drugs (yes vs. no), Eastern Cooperative Oncology Group (ECOG) performance status at the start of NK1-RA treatment (0 vs. 1-2), and intensity of chemotherapy regimen (doublet vs. triplet)...Finally, chemotherapy delays (p = 0.000009) and chemotherapy dose reductions (p = 0.0000006) were less frequently observed in primary NK1-RA users. In patients affected by gastrointestinal malignancies, a primary CINV prophylaxis with NK1-RA, 5HT3-RA, and dexamethasone might be appropriate, particularly in those situations at higher risk of emesis and in which it is important to avoid dose delays and/or dose reductions, keeping a proper dose intensity of chemotherapy drugs.
- | chloroquine phosphate / Generic mfg., leucovorin calcium / Generic mfg.
Journal: New pyrazolylpyrazoline derivatives as dual acting antimalarial-antileishamanial agents: synthesis, biological evaluation and molecular modelling simulations. (Pubmed Central) - Aug 30, 2022
Further evaluation of 5b and 6a against chloroquine-resistant strain (RKL9) of P. falciparum showed higher potency than chloroquine...Moreover, antileishmanial activity reversal of the active compounds via folic and folinic acids showed comparable results to the positive control trimethoprim, indicating an antifolate mechanism via targeting leishmanial DHFR and PTR1...In addition, docking of the most active compound against putative malarial target Pf-DHFR-TS and leishmanial PTR1 rationalised the observed activities. Molecular dynamics simulations confirmed a stable and high potential binding of 7a against leishmanial PTR1.
- | Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 29, 2022
P2, N=60, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Enrollment open, Metastases: FIND: mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 29, 2022
P2a, N=18, Recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
Molecular dynamics simulations confirmed a stable and high potential binding of 7a against leishmanial PTR1. Not yet recruiting --> Recruiting
- ||||| Retrospective data: Retrospective analysis of Australasian PURPLE #pancreaticcancer registry. n=615, median OS comparable b/t 1L gem/nab-paclitaxel (n = 376) vs FOLFIRINOX (n = 73) (11.3 vs 12.3 mos, p=0.37) but #2L PFS longer w/prior FFX (5.2 vs 2.9 mos, p=0.03 https://t.co/xU2yQlKTXN @OncoAlert (Twitter) - Aug 28, 2022
- ||||| Clinical, Checkpoint inhibition: 🤔Is there a role for checkpoint inhibition as maintenance therapy of #CRC ? @ESMO_Open https://t.co/M7RNMvZnG7 ✅MODUL chohort 2, n=446 👉 Adding atezolizumab to FP/bevacizumab after FOLFOX+bevacizumab induction for BRAFwt mCRC does not improve efficacy outcomes @myESMO (Twitter) - Aug 28, 2022
- | Journal: Myofibroblastic CAF Density, Not Activated Stroma Index, Indicates Prognosis after Neoadjuvant Therapy of Pancreatic Carcinoma. (Pubmed Central) - Aug 27, 2022
Tissue from resection specimens of n = 48 PDAC patients after neoadjuvant chemotherapy with FOLFIRINOX (FOL; n = 31), gemcitabine + nab-paclitaxel (GEM; 7) or combination treatment (COMB; 10) was compared with upfront resected matched controls (RES; 69)...Reversed prognostic association of ASI thus points to the differing significance of stromal composition after FOL, while improved prognosis with high CAF abundance suggests a synergistic effect of myofibroblasts with chemotherapy. These divergences impede usability of ASI after NT.
- || 5-fluorouracil / Generic mfg.
P1 data, Journal, Combination therapy: Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The CONKO-008 Phase I Investigation. (Pubmed Central) - Aug 27, 2022
These divergences impede usability of ASI after NT. The combination of lapatinib 1250 mg OD with platinum-containing chemotherapy is safe and feasible in patients with refractory pancreatic cancer and warrants further investigation.
- || leucovorin calcium / Generic mfg.
Leucovorin! (Twitter) - Aug 26, 2022
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Counter-Clockwise Approach for Robotic Pylorus-Preserving Pancreatoduodenectomy. (Pubmed Central) - Aug 26, 2022
The combination of lapatinib 1250 mg OD with platinum-containing chemotherapy is safe and feasible in patients with refractory pancreatic cancer and warrants further investigation. The entire surgery happens in a unique surgical field, the RUQ, which saves time by avoiding unnecessary mobilization of the bowel and favors a layer-by-layer dissection with enough space for both dissections and sutures on each step of the procedure and improving bleeding control if necessary.
- || Biomarker, Review, Journal, PD(L)-1 Biomarker, IO biomarker: Colon Cancer Pharmacogenetics: A Narrative Review. (Pubmed Central) - Aug 26, 2022
Other treatments include biological therapies and immunotherapy with drugs such as bevacizumab, panitumumab, cetuximab, and pembrolizumab...Some other mutations in the thymidylate synthase gene (TSYM), methylenetetrahydrofolate reductase gene (MTHFR), and ATP binding cassette transporter B (ABCB1 and ABCB2) affect efficacy and security of the treatments. It is important to address the clinical implication of the oncologist in the study of gene mutations than can influence in the antitumoral response and safety of colon cancer treatments.
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
Reimbursement: From an insurance/coverage standpoint, FOLFOX➕NIVO would be a category 1 recommendation. I might use that as a regimen but skip the chemo. I don’t think @NCCN draws a distinction for MSI-High in 1st line. But it probably should. @JAMAOnc @JoeChaoMD https://t.co/AigM7Ecw7f (Twitter) - Aug 26, 2022
- | Journal: Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry. (Pubmed Central) - Aug 24, 2022
However, FOLFIRINOX was associated with delayed progression. In the absence of phase III RCT data, clinicians should be comfortable using either Gemcitabine/Nab-Paclitaxel or FOLFIRINOX as first-line therapy in advanced PDAC.
- ||| leucovorin calcium / Generic mfg.
Probably not directly relevant, but RCT from the AIDS PCP literature suggest leucovorin increases mortality - https://t.co/3HWLirXvxJ (Twitter) - Aug 24, 2022